Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
- Forschungszentrum Jülich
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- Leibniz
- Leibniz-Institute for Food Systems Biology at the Technical University of Munich
- Senckenberg Gesellschaft fuer Naturforschung
- Technical University of Munich
- Academic Europe
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- Eberhard Karls University Tübingen
- European XFEL
- Friedrich Schiller University Jena •
- Helmholtz Zentrum Hereon
- Helmholtz-Zentrum Hereon
- Helmholtz-Zentrum für Infektionsforschung GmbH
- Justus Liebig University Giessen •
- Ludwig-Maximilians-Universität München •
- Max Planck Institute for Sustainable Materials •
- University of Bremen •
- University of Cologne
- cellumation GmbH
- 10 more »
- « less
-
Field
-
-structured doctoral training programme. Excellent early-stage researchers from all over the world are enabled to finish their third-cycle education at a logistic location of long-standing tradition. The IGS is
-
Deutsches Zentrum für Neurodegenerative Erkrankungen | Bonn, Nordrhein Westfalen | Germany | 3 months ago
19 Jan 2026 Job Information Organisation/Company Deutsches Zentrum für Neurodegenerative Erkrankungen Research Field Neurosciences Researcher Profile First Stage Researcher (R1) Application Deadline
-
state-of-the-art concepts, theories, methodologies and approaches. At the same time, IPP members are encouraged to pursue independent research from an early stage in their academic careers onwards
-
19 Jan 2026 Job Information Organisation/Company Forschungszentrum Jülich Research Field All Researcher Profile First Stage Researcher (R1) Application Deadline 19 Jan 2038 - 03:14 (UTC) Country
-
9 Feb 2026 Job Information Organisation/Company University of Cologne Department Institute for Genetics Research Field Biological sciences » Biology Researcher Profile First Stage Researcher (R1
-
) in an experimental model of multiple sclerosis (MS). This project builds on recent findings from the phase III Hercules trial (Fox et al., NEJM 2025) showing therapeutic effects of BTK inhibition in